1 Interpreting Wastewater SARS-CoV-2 Results using Bayesian

2	Analysis
3	
4	Kyle Curtis [*] , Raul A. Gonzalez
5	
6	Hampton Roads Sanitation District, 1434 Air Rail Avenue, Virginia Beach, VA 23455
7	
8	Keywords
9	SARS-CoV-2
10	COVID-19
11	Bayesian Analysis
12 13	Wastewater Surveillance RT-PCR
14	
15	
16	
17	

18 Abstract

19	Wastewater surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven a
20	practical complement to clinical data for assessing community-scale infection trends. Clinical assays,
21	such as the CDC-promulgated N1, N2, and N3 have been used to detect and quantify viral RNA in
22	wastewater but, to date, have not included estimates of reliability of true positive or true negative.
23	Bayes' Theorem was applied to estimate Type I and Type II error rates for detections of the virus in
24	wastewater. Conditional probabilities of true positive or true negative were investigated when one
25	assay was used, or multiple assays were run concurrently. Cumulative probability analysis was used to
26	assess the likelihood of true SARS-CoV-2 detection using multiple samples. Results demonstrate highly
27	reliable positive (>0.86 for priors >0.25) and negative (>0.80 for priors = 0.50) results using a single
28	assay. Using N1 and N2 concurrently caused greater reliability (>0.99 for priors <0.05) when results
29	concurred but generated potentially counterintuitive interpretations when results were discordant.
30	Regional wastewater surveillance data was investigated as a means of setting prior probabilities.
31	Probability of true detection with a single marker was investigated using cumulative probability across
32	all combinations of positive and negative results for a set of three samples. Findings using a low (0.11)
33	and uniformed (0.50) initial prior resulted in high probabilities of detection (>0.95) even when a set of
34	samples included one or two negative results, demonstrating the influence of high sensitivity and
35	specificity values. Analyses presented here provide a practical framework for understanding analytical
36	results generated by wastewater surveillance programs.

37

38 Introduction

The on-going coronavirus disease-2019 (COVID-19) pandemic has reached most regions of the
 world, with global cases and deaths currently greater than 185 million and 4 million, respectively (Dong

41	et al., 2020). COVID-19 wastewater surveillance has emerged as a complementary epidemiological tool
42	used to identify community level infection trends, as an early warning system, and even to screen for
43	infected individuals at the building level. The dominant analytical techniques to quantify severe acute
44	respiratory syndrome 2 (SARS-CoV-2), the virus that causes COVID-19, are PCR-based (e.g., RT-qPCR, RT-
45	dPCR) and use clinical assays. Globally, the research community (Bivins et al., 2020; Naughton et al.
46	2021) has made considerable progress in effectively applying this tool to quantify the virus in
47	wastewater and observe community-scale trends. The next phase of implementation should focus on
48	appropriate interpretation of results with respect to confidence or probability.
49	Bayes' Theorem can be used to calculate results in terms of likelihood, or in the language of
50	Bayesian statistics, posterior probability. Because of type I and II errors in PCR data, results are more
51	accurately reported in terms of probability, which includes a consideration of prior likelihood of an event
52	as well as false positive and negative rates. This approach computes the conditional probability of
53	reliable result (true negative or true positive), then continually updates prior assumptions as new
54	information is acquired. A Bayesian framework for interpreting analytical results from environmental
55	samples has been applied in the field of microbial source tracking (MST) (Kildare et al. 2007; Johnston et
56	al. 2013, Curtis and Gonzalez 2019, Chen et al. 2021). Here PCR markers for human-associated fecal
57	microbes are used to identify waterways potentially impacted by wastewater. Employing a Bayesian
58	approach characterizes results in terms of contamination probability rather than simple
59	presence/absence or concentration of the marker. This method provides a quantitative way to
60	incorporate new information (e.g. recent sample results) into the interpretation of subsequent results.
61	Applying a probabilistic framework for understanding the reliability of results requires only the
62	sensitivity and specificity of the analytical test and the ability to set a prior. Here we examine this
63	approach using the Centers for Disease Control (CDC) SARS-CoV-2 panel (N1, N2, N3) under a variety of

wastewater surveillance scenarios. The likelihood of true positive and true negative is examined using
individual assays across a range of prior probabilities and also using multiple assays concurrently. A
proposed technique for setting realistic priors based on wastewater sampling results is described using
data from a wastewater surveillance network with nine treatment facilities in southeastern Virginia.
Finally, cumulative probability is used to investigate the interpretation of multiple sample results under
two scenarios.

- 70
- 71 Methods

72 CDC Assay Sensitivity and Specificity

73 The CDC SARS-CoV-2 real-time reverse transcription PCR panel (N1, N2, N3) was used to assess 74 the likelihood that wastewater samples contained SARS-CoV-2 RNA based on analytical results, and 75 assay sensitivity and specificity. These assays were developed for clinical identification of SARS-CoV-2 76 infection but have been widely applied to environmental samples, particularly wastewater, for virus 77 detection and enumeration (e.g. Stadler et al. 2020, Agrawal et al. 2021, McClary-Gutierrez 2021). The 78 specificity of each assay was tested in-vitro by Lu et al. (2020) finding N1, N2 and N3 assays with 79 specificity values of 1.0, 1.0, and 0.955 respectively. Specificity can be described as the tendency of an 80 assay to not detect the target of interest when it is absent and is calculated by dividing the number of 81 true negative values by the number of test samples which did not contain the target. Thus, a specificity 82 of 0.955 suggests a false-negative rate of 4.5%.

The sensitivity of an assay describes its ability to detect the target when it is present.
Wastewater sensitivity values were calculated using regional clinical data from the Virginia Department
of Health (https://www.vdh.virginia.gov/coronavirus/) and SARS-CoV-2 wastewater results (Gonzalez et

86	al. 2020). Clinical PCR positive case counts by zip code for all zip codes within the 9 wastewater
87	treatment facility sewersheds in Hampton Roads, Virginia were gathered from May 15, 2020 through
88	November 17, 2020. True positives were defined as when a weekly wastewater sample from a facility
89	was positive and at least one zip code in the facility's catchment had a clinically confirmed infected
90	individual that week. For each of the 3 assays, the number of weekly wastewater samples from the 9
91	facilities were pooled. The number of samples with a true positive were divided by the total number of
92	samples to determine the sensitivity of each assay in wastewater. The sensitivity for N1, N2, and N3
93	assays are 75% (200/266), 83% (220/266), and 80% (212/266) respectively. Sensitivity and specificity as
94	used in subsequent equations are described below.
95	
96	Sensitivity (Se) and Specificity (Sp);
97	$Se = P(A^+ CoV2^+)$
98	$Sp = P(A^{-} CoV2^{-})$
99	where;
100	Se = assay sensitivity
101	Sp = assay specificity
102	A^+ = a positive detection with a given assay
103	A ⁻ = a negative analytical result with a given assay
104	
105	

106 Bayes' Theorem

- 107 Bayes' Theorem (eq 1) was applied to CDC assay sensitivity and the wastewater-derived specificity to
- 108 investigate the likelihood that SARS-CoV-2 is present in wastewater samples given positive and negative
- analytical results.

110

111 Equation 1.

112
$$P(CoV2^{+}|A^{+}) = \frac{P(A^{+}|CoV2^{+}) * P(CoV2^{+})}{[P(A^{+}|CoV2^{+}) * P(CoV2^{+})] + [P(A^{+}|CoV2^{-}) * P(CoV2^{-})]}$$

113

- 114 where;
- 115 CoV2⁺ = SARS-CoV-2 is present
- 116 $CoV2^{-} = SARS-CoV-2$ is absent

118	The posterior probability that SARS-CoV-2 is present in a sample given detection of each assay (N1, N2,
119	N3) was tested across all possible priors (0.0-1.0) using Equation 1. A similar conditional probability was
120	derived to test the likelihood that SARS-CoV-2 is absent from a sample given a negative assay result and
121	was also tested across all priors.
122	As noted, the specificity of the N1 and N2 assays determined by Lu et al. were 1.0. A specificity value of
123	1.0 guarantees the absence of false positive results regardless of assay sensitivity and prior probability.
124	As a result, it is difficult to observe the effect of differing approaches for setting priors and the

- 125 implications of using one or multiple assays. To investigate these factors, we have used a specificity
- 126 value of 0.999 for all calculations.
- 127
- 128
- 129 Surveillance Using Multiple Assays Concurrently

130 A multiple-assay approach to environmental sampling has been supported in the field of 131 microbial source tracking (MST) (Harwood et al. 2014; Ahmed et al. 2016; Jardé et al. 2018;) and is 132 currently employed by many researchers conducting wastewater surveillance of SARS-CoV-2 (Stadler et 133 al. 2020; Peñarrubia et al. 2020; Agrawal et al. 2021). The likelihood that SARS-CoV-2 is present in a 134 sample was investigated using multiple assays concurrently. Equation 2 describes the probability that 135 SARS-CoV-2 is present given positive detection of the virus with two assays. N1 and N2 assay were 136 selected for this analysis due to CDC's recommendation to remove N3 from the clinical panel (Lu et al. 137 2020). An analogous equation was used to test the likelihood that SARS-CoV-2 is present when failing to 138 detect the virus using two assays. All combinations of N1 and N2 detection and non-detection were 139 tested across the range of possible priors (0.0-1.0).

- 140
- 141 Equation 2.

142
$$P(CoV2^+|A_1^+ \cap A_2^+) = \frac{Se_1 * Se_2 * P(CoV2^+)}{Se_1 * Se_2 * P(CoV2^+) + (1 - Sp_1) * (1 - Sp_2) * P(CoV2^-)}$$

143

144 where;

147
$$A_i^+$$
 = detection of assay

148
$$A_i^-$$
 = failing to detect assay i

149 Prior Probabilities Based on Wastewater Detection

150 Wastewater surveillance data using the N2 assay and the N1 and N2 assays concurrently were 151 used to set priors based on percent positive wastewater samples. In this case the prior probability of 152 SARS-CoV-2 in wastewater was set as the percent of samples which were positive for one or both assay 153 in the week prior. Wastewater data for these analyses come from the wastewater surveillance program 154 being conducted by the Hampton Roads Sanitation District (HRSD) and comprise a raw influent sample 155 from each of 9 regional treatment facilities. For a detailed description of sampling and analytical 156 methodologies see Gonzalez et al. 2020. Using wastewater-derived priors, posterior probability of SARS-157 CoV-2 presence was calculated for wastewater samples using N2 alone and N1 and N2 concurrently. For 158 samples that were negative for N2 or both N1 and N2 the posterior probability that SARS-CoV-2 is 159 absent in a given wastewater sample was reported.

160

161 *Cumulative Probability from Multiple Samples*

162 The cumulative probability of SARS-CoV-2 based on results from three separate samples was 163 investigated for two scenarios representing a comparatively low and high initial prior. The low initial 164 prior (0.11) was based on the lowest possible non-zero value for percent positive treatment facilities (1 165 of 9 facilities with a detection) in the Hampton Roads wastewater surveillance network. The high initial

166 prior (0.50) was used to examine a situation where there is no reliable way to estimate prior likelihood 167 and thus priors are uninformed. Cumulative probability of the presence of SARS-CoV-2 was calculated 168 using Equation 4 for each sample and the resulting posterior probability was used as the prior for 169 subsequent samples. Equation 4. 170 171 $P(CoV2^+)_C = 1 - \Pi (1 - P(CoV2^+|A^+_-))$ 172 173 Where; 174 P(CoV2⁺)_c = cumulative probability of SARS-CoV-2 $P(CoV2^{+}|A\pm) = probability of SARS-CoV-2 given a positive or negative assay$ 175 176 177 178 **Results and Discussion** 179 Confidence Using a Single Assay 180 Bayes' Theorem was applied in conjunction with sensitivity and specificity values for the three 181 CDC assays to calculate posterior probabilities of true positive and true negative across all possible 182 priors (Figure 1). The high specificity values of each assay resulted in expectedly high posterior 183 probabilities of SARS-CoV-2 given a positive analytical result (Figure 1a). The resulting curves suggest 184 that when N1 or N2 are used, a positive analytical result is highly reliable (>0.97), even at priors below 185 0.05. While not as overwhelming as N1 or N2, the N3 assay also generated highly reliable positive

186 results with posterior probabilities of SARS-CoV-2 >0.86 for priors >0.25. The marginally increased 187 likelihood of false positive results for N3 was expected given the slightly lower specificity (0.955). As described by Lu et al., the N3 assay was intentionally designed to also detect SARS-CoV, resulting in a 188 189 lower specificity value when cross-reactivity was tested against closely related respiratory viruses. The 190 likelihood of obtaining a true negative result was high with all assays when SARS-CoV-2 was absent 191 (Figure 1b). Values denoting likelihood of true negative result are more similar among assays than those 192 for true positives, owing to the similarity in calculated sensitivity values. Findings suggest that when 193 using an uninformed prior (0.50) a single assay generates acceptable confidence (0.80) in negative 194 results. Given no additional data to inform prior selection all assays performed well and result in a 195 reasonably high likelihood of true negative results. If there is reason to reduce the estimate of prior 196 probability the reliability of a true negative increases dramatically and is greater than 0.92 for all priors 197 <0.25 (Figure 1).

198

199 Surveillance Using Multiple Assays Concurrently

200 Many COVID-19 wastewater surveillance publications have concurrently used multiple SARS-201 CoV-2 assays. When different combinations of N1 and N2 assay results were tested across all priors, the 202 resulting posterior probabilities for SARS-CoV-2 presence track in a generally predictable manner (Figure 203 2). When both assays detect the virus there is an exceedingly high probability (>0.99) that this detection 204 is reliable, even at very low priors (0.005). Similarly, when either assay is used individually and detects 205 the virus, these results are also highly reliable, as described in the previous section. Discordant results 206 (N1+/N2- or N2+/N1-) using two assays also yields a high probability that SARS-CoV-2 is present (>0.87), 207 even when priors are low (0.05). This is a potentially counterintuitive result which requires an 208 understanding of test characteristics (sensitivity and specificity) as well as the effect of prior probability

209 to appropriately interpret. Failing to consider these results in a Bayesian framework, one might tacitly 210 assign a likelihood of 0.5 to the probability that SARS-CoV-2 is present, given that two highly accurate 211 tests yielded conflicting results. Such an interpretation not only underestimates the likelihood that 212 SARS-CoV-2 is present, it also provides no more information about SARS-CoV-2 presence in wastewater 213 than what was known prior to sampling. In other words, this interpretation suggests that the virus is just 214 as likely present as not. Alternatively, one might assume a low prior probability that SARS-CoV-2 is 215 present, given low community incidence at the time of sampling, and therefore conclude that conflicting 216 results actually suggest the virus is absent by considering the one positive result a false positive. This 217 would also be an incorrect interpretation, given what is known about the sensitivity and specificity of 218 these assays. The implication of this interpretation is assigning a 0.0 probability that SARS-CoV-2 is 219 present when in fact there is a >0.93 likelihood that it is present for all priors above 0.10.

220

221 Wastewater Detections to Inform Priors

222 One strategy for selecting prior probability of SARS-CoV-2 in wastewater samples is to use 223 recent wastewater surveillance results. Surveillance programs often sample at routine intervals, and 224 some include multiple facilities. Therefore, a simple metric such as percent positive samples over recent 225 weeks or across multiple facilities can be used to inform prior probability. Relatively large priors (0.39-226 1.0) resulted when percent positive facilities were calculated using the Hampton Roads surveillance data 227 due to the ubiquity of the virus in this region for the study period. With most priors being >0.50 positive 228 results are highly reliable for all samples, regardless if one or both assays were used (Fig 3). These 229 findings suggest that a single assay likely provides sufficient confidence in positive results when 230 detections are routinely seen at monitored facilities, causing priors to be set relatively high.

231 Conversely, the likelihood of true negative is somewhat driven down (Figure 3) when 232 wastewater-derived priors result in high values. This effect is understandable considering that 233 numerous recent detections should suggest a greater likelihood of detection for the current set of 234 samples. The consequence of high priors in constraining reliability of negative results is clearly shown in 235 the 7/21/20 data from Figure 3. This figure shows the likelihood of true positive for samples given 236 detection of one or both assay and likelihood of true negative when one or both assays fail to detect 237 viral RNA. Here, given a prior probability of 83% that SARS-CoV-2 is present, a single negative N2 result 238 indicates a 54% likelihood of true negative. Finding negative results for both assays increases the 239 likelihood of true negative, but only to 74%. This is a significant departure for the reliability associated 240 with concordant negative results when priors are lower (<0.15), which approaches 100%. In a scenario 241 of high priors based on numerous recent detections a negative result should be assigned less reliability 242 than one when few recent samples are positive, given that wastewater detection of viral RNA is an 243 indication of community incidence for a catchment. However, such an interpretation may not be 244 intuitive if one simply considers the sensitivity of the assay but fails to account for the prior likelihood of 245 detection.

246 Finding conflicting results when running multiple assays in the context of higher, wastewater-247 derived priors also produces potentially difficult to interpret results. For the range of wastewater-248 derived priors tested (0.39-1.0), discordant results regardless of which assay was detected, provide 249 strong evidence that SARS-CoV-2 is present (Figure 3). As described above, failing to consider prior 250 probability of detection could lead a researcher to interpret conflicting results as a 0.5 likelihood that 251 SAR-CoV-2 RNA is present in the sample. Interpretation using a Bayesian framework would suggest that, 252 even at the lowest prior for which there were conflicting results (0.56), the likelihood that the virus is 253 present is >0.99.

254

255 Multiple Samples

256 Collecting multiple samples is an effective alternative for increasing reliability in results while 257 avoiding the need to run multiple assays. This approach generates high confidence via the cumulative 258 probability of true positive/negative results across samples, rather than the intersection of 259 positive/negative results for two or more assays. A multiple sample strategy was applied using a prior of 260 0.11 to examine the effect of a wastewater-derived prior for a situation where one of the nine facilities 261 in the HRSD surveillance network had a positive detection in the previous week. At this prior, any 262 combinations of samples that include a positive result yield >0.95 likelihood that viral RNA is present. A 263 negative result in sample one reduces the likelihood that SARS-CoV-2 is present from 0.11 to 0.02. In 264 this scenario the second sample is highly informative. Finding a positive result in sample two, even after 265 a negative for sample one, yields a 0.95 likelihood that the virus is present. High cumulative probability 266 that the virus is present given conflicting results from two samples using a single assay is consistent with 267 the analogous finding of high likelihood given the intersection of two conflicting, different assays run on 268 a single sample. With no detection in sample one, a second negative result has little impact on the 269 cumulative probability, which is 0.025, giving good evidence that the virus is absent. This pattern 270 continues for each sample three endpoint, wherein any positive result drives the cumulative probability 271 that SARS-CoV-2 is present in a set of three samples above 0.94 while consecutive negative results yield 272 cumulative probabilities (0.020 - 0.028) which remain one order of magnitude lower than the prior 273 (0.11).

Using an uniformed prior (0.50) results in a similarly high posterior probability (>0.99) that SARS-CoV-2 is present for all combinations of sampling results other than three consecutive negatives. A key difference with this prior is that even samples with only negative results still yield a 0.15-0.20 likelihood

277 that SARS-CoV-2 is present. As described previously, this strategy for setting priors is reasonable when 278 there is no reliable way to estimate likelihood of detecting viral RNA before samples have been 279 analyzed. Using a prior of 0.50 suggests a 50% likelihood that a sample contains the SARS-CoV-2 virus at 280 a concentration greater than the analytical limit of detection. The interaction of a prior that suggests an 281 equal chance of detecting RNA as not (0.50) with the high sensitivity and specificity of the N2 assay 282 generates some cumulative probabilities that may seem counterintuitive. The main examples include 283 sets of three samples for which two results are negative and one is positive but the cumulative 284 probability that SARS-CoV-2 is present is still >0.99. Intuitively, two negative results, regardless of where 285 they occur in the sequence of samples, seem to suggest the absence of SARS-CoV-2. Following a 286 Bayesian approach in which priors are updated each time new data is acquired helps clarify these 287 results. As described, the posterior probability from each sample is used as the prior for subsequent 288 samples. Sets of samples where the positive result occurred first in sequence results in high posterior 289 probabilities which are carried through as priors for the remaining samples. For these cases, even 290 negative downstream results yield high posterior probabilities, driven by priors of >0.99 used in samples 291 two and three. In cases where sample one is negative, the prior of 0.50 and high sensitivity and 292 specificity prevent the posterior probability from being driven below 0.14. As a result, a positive 293 detection in sample one or two results in a cumulative probability of >0.99.

294

295

296 Limitations and Assumptions

Applying a Bayesian framework for interpreting analytical findings is fundamentally driven by the
sensitivity and specificity values assigned to the assays in question, along with the assumed prior. As a
result, the accuracy of these values is highly consequential for the analysis. For this preliminary exercise,

300 in vivo specificity values similar to those reported by Lu et al. (2020) were used in conjunction with a 301 novel in situ approach to determining sensitivity values from a regional SARS-CoV-2 wastewater 302 monitoring program. As noted, specificity values of 0.999 were used in place of the 1.0 specificities 303 reported by Lu et al. (2020) for the N1 and N2 assays. The goal of this approach was to assume a false 304 positive rate of 1/1000 in order to conservatively examine the reliability of analytical results when 305 neither sensitivity nor specificity are perfect. Where possible, future studies should conduct in-house 306 specificity testing using their own analytical methodology performed on the matrix being studied to 307 derive lab-specific specificity values. A similar recommendation is suggested for deriving lab-specific 308 sensitivity values and is likely more impacted by wastewater matrix effects such as inhibition. 309 After establishing assay sensitivity and specificity, prior probability is the final value required to conduct 310 the simple conditional probability analyses described above. Prior probability is another critical piece of 311 this framework as it also exerts a significant influence on the outcome and the process for setting a 312 value may not be intuitive. Establishing the prior probability of an event or result can be challenging 313 when little is known about the system being studied. Regarding wastewater-based epidemiology one 314 suggested approach for estimating prior probability of SARS-CoV-2 detection is to use recent results 315 from the same location (e.g., the proportion of positive results from the last set or sets of samples) or 316 results from other areas within a common region. Priors may also comprise a distribution, allowing for 317 some incorporation of uncertainty. For instance, noting that clinical cases in the area of study have 318 been increasing rapidly in the preceding weeks does not suggest a specific value for use as a prior 319 probability but does provide information which should not be ignored when assessing reliability of 320 wastewater detections. Integrating this clinical information into a Bayesian analysis of wastewater

results might include setting priors using a uniform distribution of 0.51-0.99, implying that little is known

322 about the true prior probability of SARS-CoV-2 detection, but regional case data suggests that a

- detection is likelier than not. Performed this way the posterior probability is also a distribution which
- allows for uncertainty around the estimate to be easily included.

325

326

- 327 AUTHOR INFORMATION
- 328 Corresponding Author
- 329 *Corresponding author contact information
- 330 Kyle Curtis
- 331 Hampton Roads Sanitation District
- 332 1434 Air Rail Avenue
- 333 Virginia Beach, VA 23455
- 334 Email: kcurtis@hrsd.com
- 335
- 336 Author Contributions
- 337 The manuscript was written through contributions of all authors. All authors have given approval to the
- 338 final version of the manuscript.

339

340 Funding Sources

All funding for this work was provided by Hampton Roads Sanitation District.

- 342
- 343
- 344


345 **References**

346	1.	Dong, E.; Du, H.; Gardner, L. An Interactive Web-Based Dashboard to Track COVID-19 in Real
347		Time. Lancet Infect. Dis. 2020, 3099 (20), 19– 20, DOI: 10.1016/S1473-3099(20)30120-1
348	2.	Aaron Bivins, Devin North, Arslan Ahmad, Warish Ahmed, Eric Alm, Frederic Bivins, A., North, D.,
349		Ahmad, A., Ahmed, W., Alm, E., Been, F., Bhattacharya, P., Bijlsma, L., Boehm, A.B., Brown, J. and
350		Buttiglieri, G., 2020. Wastewater-based epidemiology: global collaborative to maximize
351		contributions in the fight against COVID-19.Been, Prosun Bhattacharya, Lubertus Bijlsma, Alexandria
352		B Boehm, Joe Brown, Gianluigi Buttiglieri, Vincenza Calabro, Annalaura Carducci, Sara Castiglioni,
353		Zeynep Cetecioglu Gurol, Sudip Chakraborty, Federico Costa, Stefano Curcio, Francis L de los Reyes
354		III, Jeseth Delgado Vela, Kata Farkas, Xavier Fernandez-Casi, Charles Gerba, Daniel Gerrity, Rosina
355		Girones, Raul Gonzalez, Eiji Haramoto, Angela Harris, Patricia A Holden, Md Tahmidul Islam, Davey L
356		Jones, Barbara Kasprzyk-Hordern, Masaaki Kitajima, Nadine Kotlarz, Manish Kumar, Keisuke Kuroda,
357		Giuseppina La Rosa, Francesca Malpei, Mariana Mautus, Sandra L McLellan, Gertjan Medema, John
358		Scott Meschke, Jochen Mueller, Ryan J Newton, David Nilsson, Rachel T Noble, Alexander Van Nuijs,
359		Jordan Peccia, T Alex Perkins, Amy J Pickering, Joan Rose, Gloria Sanchez, Adam Smith, Lauren
360		Stadler, Christine Stauber, Kevin Thomas, Tom Van Der Voorn, Krista Wigginton, Kevin Zhu, Kyle
361		Bibby. 2020. Wastewater-based epidemiology: global collaborative to maximize contributions in the
362		fight against COVID-19. Environmental Science and Technology, 54(13), pp.7754–7757


- 363 3. Naughton, C.C., Roman, F.A., Alvarado, A.G.F., Tariqi, A.Q., Deeming, M.A., Bibby, K., Bivins, A., Rose,
- 364 J.B., Medema, G., Ahmed, W. and Katsivelis, P., 2021. Show us the data: Global COVID-19
- 365 wastewater monitoring efforts, equity, and gaps. medRxiv.
- 4. Kildare, B.J., Leutenegger, C.M., McSwain, B.S., Bambic, D.G., Rajal, V.B. and Wuertz, S., 2007. 16S
- 367 rRNA-based assays for quantitative detection of universal, human-, cow-, and dog-specific fecal
- Bacteroidales: a Bayesian approach. Water research, 41(16), pp.3701-3715.
- 369 5. Johnston, C., Byappanahalli, M.N., Gibson, J.M., Ufnar, J.A., Whitman, R.L. and Stewart, J.R., 2013.
- 370 Probabilistic analysis showing that a combination of Bacteroides and Methanobrevibacter source
- 371 tracking markers is effective for identifying waters contaminated by human fecal
- pollution. Environmental science & technology, 47(23), pp.13621-13628.
- 373 6. Curtis, K. and Gonzalez, R.A., 2019. Integrating Bayesian Analysis and Cumulative Probability
- 374 Generates High Confidence Using a Single Microbial Source Tracking Marker. Environmental science
- 375 & technology, 53(23), pp.13929-13937.
- 376 7. Chen, H., Liu, C., Li, Y. and Teng, Y., 2021. Integrating metagenomic and Bayesian analyses to
- evaluate the performance and confidence of CrAssphage as an Indicator for tracking human sewage
- 378 contamination in China. Environmental Science & Technology, 55(8), pp.4992-5000.
- 379 8. Stadler, L.B., Ensor, K., Clark, J.R., Kalvapalle, P., LaTurner, Z.W., Mojica, L., Terwilliger, A.L., Zhuo, Y.,
- Ali, P., Avadhanula, V. and Bertolusso, R., 2020. Wastewater Analysis of SARS-CoV-2 as a Predictive
- 381 Metric of Positivity Rate for a Major Metropolis. MedRxiv.
- 382 9. Agrawal, S., Orschler, L. and Lackner, S., 2021. Long-term monitoring of SARS-CoV-2 RNA in
- 383 wastewater of the Frankfurt metropolitan area in Southern Germany. Scientific reports, 11(1), pp.1-
- 384 7.
- 10. McClary-Gutierrez, J., Mattioli, M., Marcenac, P., Silverman, A., Boehm, A., Bibby, K., Balliet, M.,
- 386 Gerrity, D., Griffith, J., Holden, P. and Katehis, D., 2021. Sars-Cov-2 Wastewater Surveillance for

- Public Health Action: Connecting Perspectives From Wastewater Researchers and Public Health
 Officials During a Global Pandemic.
- 389 11. Lu, X., Wang, L., Sakthivel, S.K., Whitaker, B., Murray, J., Kamili, S., Lynch, B., Malapati, L., Burke,
- 390 S.A., Harcourt, J. and Tamin, A., 2020. US CDC real-time reverse transcription PCR panel for
- detection of severe acute respiratory syndrome coronavirus 2. Emerging infectious diseases, 26(8),
- 392 p.1654.
- 12. Gonzalez, R., Curtis, K., Bivins, A., Bibby, K., Weir, M.H., Yetka, K., Thompson, H., Keeling, D.,
- 394 Mitchell, J. and Gonzalez, D., 2020. COVID-19 surveillance in Southeastern Virginia using
- 395 wastewater-based epidemiology. Water research, 186, p.116296.
- 13. Harwood, V.J., Staley, C., Badgley, B.D., Borges, K. and Korajkic, A., 2014. Microbial source tracking
- 397 markers for detection of fecal contamination in environmental waters: relationships between
- pathogens and human health outcomes. FEMS microbiology reviews, 38(1), pp.1-40.
- 399 14. Ahmed, W., Sidhu, J.P., Smith, K., Beale, D.J., Gyawali, P. and Toze, S., 2016. Distributions of fecal
- 400 markers in wastewater from different climatic zones for human fecal pollution tracking in Australian
- 401 surface waters. Applied and environmental microbiology, 82(4), pp.1316-1323.
- 402 15. Jardé, E., Jeanneau, L., Harrault, L., Quenot, E., Solecki, O., Petitjean, P., Lozach, S., Chevé, J. and
- 403 Gourmelon, M., 2018. Application of a microbial source tracking based on bacterial and chemical
- 404 markers in headwater and coastal catchments. Science of The Total Environment, 610, pp.55-63.
- 405 16. Peñarrubia, L., Ruiz, M., Porco, R., Rao, S.N., Juanola-Falgarona, M., Manissero, D., López-Fontanals,
- 406 M. and Pareja, J., 2020. Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk
- 407 of loss of sensitivity by new genomic variants during the COVID-19 outbreak. International Journal of
- 408 Infectious Diseases, 97, pp.225-229.

412 Figure 1.




414 Posterior probability of true positive (top) and true negative (bottom) result for the N1, N2, and N3






424 Figure 2.



Posterior probability that SARS-CoV-2 nucleic acid is present given combinations of results using one or
both of the N1 and N2 assays. Posteriors plotted across all possible prior probabilities that SARS-CoV-2
is present.






Posterior probability of true positive or true negative using the N2 assay (top). The middle panel shows the likelihood of true positive given detection with one or both of N1 and N2 assays and true negative when both assays used concurrently fail to detect the virus. The bottom panel indicates the number of treatment facilities (n=9) in which the virus was detected. These values are used as priors for calculating posterior probabilities plotted in the top and middle panels.



446



447

448

449 Cumulative probability that SARS-CoV-2 nucleic acid is present given two initial priors (0.11, 0.50).

450 Cumulative posteriors are plotted across three sampling events with all combinations of

451 positive/negative results displayed.